Our short, quick and targeted approach mixes qualitative and quantitative analysis. By applying market data, history, science and quantitative methods; we synthesize metrics of pricing the RegMed universe. RMI incorporates market dynamics, answering crucial questions and generating actionable investment recommendations.
Understanding and knowing the answer as the release is issued requires a historical knowledge of sector pricing to more than “questimate” share perception and rebounds.
June 18, 2018
Solid Biosciences (SLDB) clinical hold removed on SGT-001 DMD (Duchenne muscular dystrophy) treatment
June 7, 2018
MiMedx Group (MDXG) crashes after news of a 5 year restatement and CFO departs
April 23, 2018
Pluristem (PSTI) and Indiana University evaluating PLX-R18 in Acute Radiation Syndrome (ARS)
April 16, 2018
Organovo (ONVO) Achieves liver disease and intestinal 3D bio-printed tissue models milestones - BUY
April 12, 2018
Organovo Holdings (ONVO) presents data on creating drug profile of chronic liver disease progression - BUY
April 10, 2018
Caladrius Biosciences (CLBS) receives SAKIGAKE Expedited Review Designation in Japan for CLBS12 for treating CLI - BUY
April 9, 2018
Cesca Therapeutics (KOOL) proposes a $10 M unit and attached warrant offering in new prospectus
April 9, 2018
Regenxbio (RGNX) license with AveXis (AVXS) on Novartis (NVS) acquisition news triggers $180 M pay-day
April 3, 2018
Cellectis (CLLS) and Allogene Therapeutics accelerate allogeneic off-the-shelf CAR T Therapies
March 28, 2018
bluebird bio (BLUE)and Celgene (CELG) ink agreement to co-develop/promote Anti-BCMA CAR T cell therapy (bb2121) in the US
March 26, 2018
MiMedx (MDXG) positive data P2B clinical trial Of AmnioFix® Injectable In treatment Of Plantar Fasciitis
March 19, 2018
Fate Therapeutics (FATE) dished additional safety data from P1 Stage of PROTECT Clinical Trial of ProTmune™
March 13, 2018
BioTime (NYSEMKT: BTX) Submits CE Mark Application for EU Approval of Renevia®
March 13, 2018
Caladrius Biosciences (CLBS) Doses1st patient with CLBS12 in P2 Critical Limb Ischemia (CLI) Trial in Japan
March 6, 2018
Fibrocell (FCSC) FDA Allowance of IND for FCX-013 for the treatment of Moderate to Severe Localized Scleroderma
January 30, 2018
Bellicum Pharmaceuticals (BLCM) takes a big hit as FDA imposes clinical hold on BPX-501
January 26, 2018
Verastem (VSTM) presents pre-clinical data of Duvelisib in combination with co-stimulatory antibodies in a B Cell Lymphoma Model
January 24, 2018
Spark Therapeutics (ONCE) and Novartis (NVS) enter into a Licensing/Supply Agreement with upfront fee of $105 M
January 9, 2018
Histogenics Corporation (HSGX), Receipt of $10 Million Up-front Payment for Japanese Neocart Agreement
January 5, 2018
Takeda Pharmaceutical intents to acquire TiGenix (Brussels and NASDAQ: TIG)
January 3, 2018
Sangamo Therapeutics (SGMO) $12 million collaboration with Pfizer (PFE) on a gene therapy for two neuro-degenerative disorders
January 2, 2018
Vericel Corporation (VCEL initiated a License Agreement with Innovative Cellular Therapeutics (ICT)
December 22, 2017
Biostage (BSTG) the swindle scheme continues with a 1-for-20 reverse split ratio effective 12/22/17
December 18, 2017
Biostage (BSTG): Ponzi or Pyramid scheme or a combination of both …?
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his thirteenth (13th) year at RegMed Investors
© 2018 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.